Ann Lab Med.  2023 May;43(3):299-302. 10.3343/alm.2023.43.3.299.

Prevalence of Anti-PF4 Antibodies After First and Second ChAdOx1 nCoV-19 Vaccinations in Women With Adverse Events: A Brief Report and Literature Review

• Choe KW
• Lim YK
• Kweon OJ
• Lee MK
• Chung JW
• Kim HR

• KMID: 2551715
• DOI: http://doi.org/10.3343/alm.2023.43.3.299

Figure

• 

  Fig. 1 Correlation between SARS-CoV-2 antibodies and anti-PF4 antibodies. (A) Correlation between Euroimmun anti-SARS-CoV-2 IgG and anti-PF4 antibodies after the second vaccination. (B) Correlation between sVNT neutralizing antibodies against anti-PF4 antibodies after the second vaccination. This line corresponds to the regression line describing the data pairs. Abbreviations: R, Pearson correlation coefficient; Rs, Spearman’s rank correlation coefficient; OD, optical density; sVNT, surrogate virus neutralization test.

Reference

1. Franchini M, Liumbruno GM, Pezzo M. 2021; COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol. 107:173–80. DOI: 10.1111/ejh.13665. PMID: 33987882. PMCID: PMC8239516.

2. Scully M, Singh D, Lown R, Poles A, Solomon T, Levi M, et al. 2021; Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 384:2202–11. DOI: 10.1056/NEJMoa2105385. PMID: 33861525. PMCID: PMC8112532.

3. Park JY, Choi SH, Chung JW, Hwang MH, Kim MC. 2021; Systemic adverse events and use of antipyretics predict the neutralizing antibody positivity early after the first dose of ChAdOx1 coronavirus disease vaccine. J Clin Med. 10:2844. DOI: 10.3390/jcm10132844. PMID: 34199053. PMCID: PMC8268750.

4. Adeboye A, Hart R, Senapathi SH, Ali N, Holman L, Thomas HW. 2021; Assessment of functional pain score by comparing to traditional pain scores. Cureus. 13:e16847. DOI: 10.7759/cureus.16847. PMID: 34522490. PMCID: PMC8425136.

5. Terpos E, Politou M, Ntanasis-Stathopoulos I, Karalis V, Merkouri E, Fotiou D, et al. 2021; High prevalence of anti-PF4 antibodies following ChAdOx1 nCov-19 (AZD1222) vaccination even in the absence of thrombotic events. Vaccines (Basel). 9:712. DOI: 10.3390/vaccines9070712. PMID: 34358129. PMCID: PMC8309977.

6. Thiele T, Ulm L, Holtfreter S, Schönborn L, Kuhn SO, Scheer C, et al. 2021; Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2. Blood. 138:299–303. DOI: 10.1182/blood.2021012217. PMID: 33988688. PMCID: PMC8129797.

7. Kim JA, Bang HI, Shin JW, Park Y, Kim S, Kim MY, et al. 2022; Immunogenicity of third-dose BNT162b2 mRNA vaccine following two doses of ChAdOx1 in health care workers: a prospective longitudinal study. Ann Lab Med. 42:688–92. DOI: 10.3343/alm.2022.42.6.688. PMID: 35765878. PMCID: PMC9277035.

8. Sørvoll IH, Horvei KD, Ernstsen SL, Laegreid IJ, Lund S, Grønli RH, et al. 2021; An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination. J Thromb Haemost. 19:1813–8. DOI: 10.1111/jth.15352. PMID: 33909350. PMCID: PMC8237070.

9. Platton S, Bartlett A, MacCallum P, Makris M, McDonald V, Singh D, et al. 2021; Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination. J Thromb Haemost. 19:2007–13. DOI: 10.1111/jth.15362. PMID: 33973336. PMCID: PMC8236994.

10. Satoh T, Tanaka Y, Okazaki Y, Kaburaki J, Ikeda Y, Kuwana M. 2012; Heparin-dependent and -independent anti-platelet factor 4 autoantibodies in patients with systemic lupus erythematosus. Rheumatology (Oxford). 51:1721–8. DOI: 10.1093/rheumatology/kes145. PMID: 22718864.